Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
33.06(c) 32.95(c) 32.42(c) 32.41(c) 31.4(c) Last
1 746 651 1 196 712 811 942 932 906 1 013 983 Volume
-3.36% -0.33% -1.61% -0.03% -3.12% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 26,1 M - -
Net income 2021 -671 M - -
Net cash position 2021 256 M - -
P/E ratio 2021 -3,87x
Yield 2021 -
Sales 2022 127 M - -
Net income 2022 -533 M - -
Net cash position 2022 291 M - -
P/E ratio 2022 -5,40x
Yield 2022 -
Capitalization 2 732 M 2 732 M -
EV / Sales 2021 94,9x
EV / Sales 2022 19,3x
Nbr of Employees 445
Free-Float 79,9%
More Financials
Company
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The CompanyÔÇÖs lead product candidate is APL-2. APL-2 is Phase III clinical trials developed... 
Sector
Pharmaceuticals
Calendar
09/27 | 08:40amPresentation
More about the company
Ratings of Apellis Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about APELLIS PHARMACEUTICALS, INC.
09/20APELLIS PHARMACEUTICALS : to Present at the 2021 Cantor Virtual Global Healthcare Conferen..
AQ
09/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/10Take-Two, Apellis fall; Dave & Buster's, Endo rise
AQ
09/10Health Care Stocks Ail During Friday Trading
MT
09/10APELLIS PHARMACEUTICALS : Baird Adjusts Apellis Pharmaceuticals' Price Target to $75 from ..
MT
09/10APELLIS PHARMACEUTICALS : Goldman Sachs Adjusts Apellis Pharmaceuticals' Price Target to $..
MT
09/10APELLIS PHARMACEUTICALS : Roth Capital Adjusts Apellis Pharmaceuticals' Price Target to $4..
MT
09/10APELLIS PHARMACEUTICALS : Oppenheimer Adjusts Apellis Pharmaceuticals PT to $65 From $80, ..
MT
09/10APELLIS PHARMACEUTICALS : JPMorgan Adjusts Apellis Pharmaceuticals' Price Target to $57 fr..
MT
09/10APELLIS PHARMACEUTICALS : BMO Capital Adjusts Apellis Pharmaceuticals' Price Target to $69..
MT
09/10APELLIS PHARMACEUTICALS : Needham Adjusts Apellis Pharmaceuticals' Price Target to $70 fro..
MT
09/10APELLIS PHARMACEUTICALS : Wedbush Downgrades Apellis Pharmaceuticals to Neutral From Outpe..
MT
09/10APELLIS PHARMACEUTICALS' : Study Results for Eye Disease Treatment a 'Mixed Bag' Scenario,..
MT
09/10APELLIS PHARMACEUTICALS : Credit Suisse Lowers Apellis Pharmaceuticals' PT to $38 from $50..
MT
09/10Health Care Stocks Advance Premarket Friday
MT
More news
News in other languages on APELLIS PHARMACEUTICALS, INC.
09/10Les actions du secteur de la santé en baisse pendant la séance de vendredi
09/10Les résultats de l'étude d'Apellis Pharmaceuticals sur le traitement des maladies ocula..
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | APLS | US03753U1060 | MarketScreener
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 31,40 $
Average target price 68,13 $
Spread / Average Target 117%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
APELLIS PHARMACEUTICALS, INC.-45.10%2 732
CSL LIMITED10.18%103 032
WUXI BIOLOGICS (CAYMAN) INC.14.59%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336